Stabilized external preparation comprising thymosin beta 4 as an active ingredient
The present invention relates to a stabilized external preparation comprising thymosin beta 4 (Tβ4) as an active ingredient. More specifically, the present invention relates to a therapeutically effective external preparation with improved stability and biological activity of Tβ4. The preparation according to the present invention provides Tβ4 in a stable state by maintaining the biological activity of Tβ4 and minimizing the generation of Tβ4 sulfoxide through oxidization reactions and multimers through aggregation.
1. A method for treating skin damage of a subject, comprising administering an external preparation to a damaged site of a skin of the subject,
wherein the treatment of the skin damage includes wound closure and tissue regeneration;
wherein the external preparation comprises
thymosin beta 4 (Tβ4) as an active ingredient in an amount of 172 mg based on the total amount 548 g of the external preparation,
a phosphate buffer;
an additive that is propylene glycol in an amount of 5.75 g and/or disodium-EDTA dihydrate in an amount of 63 mg, both based on the total amount 548 g of the external preparation; and
a sodium carboxymethyl cellulose as a viscosifier, in an amount of 14.4 g based on the total amount 548 g of the external preparation; and
wherein the external preparation has a pH of 5.5-6.0.
2. The method of claim 1 , wherein the skin damage is pressure ulcer, foot ulcer, epidermolysis bullosa, oral mucositis, or hidradenitis suppurativa.
3. The method of claim 2 , wherein the skin damage comprises inflammation.
4. The method of claim 1 , wherein the viscosity (cP) of the external preparation is in a range of 3 to 100,000 at 25° C.
5. The method of claim 1 , wherein the external preparation is formulated into a form of a gel, a cream, a paste, an ointment, a liniment, a lotion, a hydrogel or an aerosol.
6. A method for treating skin damage of a subject, comprising administering an external preparation to a damaged site of a skin of the subject,
wherein the treatment of the skin damage includes wound closure and tissue regeneration;
wherein the external preparation comprises
thymosin beta 4 (Tβ4) as an active ingredient in an amount of 172 mg based on the total amount 548 g of the external preparation,
a phosphate buffer,
an additive that is propylene glycol in an amount of 5.75 g and/or disodium-EDTA dihydrate in an amount of 63 mg, both based on the total amount 548 g of the external preparation; and
a sodium carboxymethyl cellulose as a viscosifier, in an amount of 14.4 g based on the total amount 548 g of the external preparation,
sterile water,
sodium chloride, and
HCl to adjust a pH of the external preparation to 5.5-6.0.